Phase 2 Trial of PRM-151, an Anti-Fibrotic Agent, in Patients with Myelofibrosis: Stage 1 Results S. Verstovsek1, R. Mesa2, L. Foltz3, V. Gupta4, J. Mascarenhas5, E. Ritchie6, R. Hoffman5, R. Silver6, W. J. Hong8, M. Kre

First Page		Document Content
Date: 2014-06-13 01:07:42 Polycythemia vera Essential thrombocytosis Fibrosis Medicine Myeloproliferative disease Myelofibrosis		Phase 2 Trial of PRM-151, an Anti-Fibrotic Agent, in Patients with Myelofibrosis: Stage 1 Results S. Verstovsek1, R. Mesa2, L. Foltz3, V. Gupta4, J. Mascarenhas5, E. Ritchie6, R. Hoffman5, R. Silver6, W. J. Hong8, M. Kre Add to Reading List Source URL: www.promedior.com Download Document from Source Website File Size: 1,74 MB Share Document on Facebook

	HAEMATOLOGY AUDIT TEMPLATE DocID: 1pL02 - View Document
	NOMINATION FORM FOR MPN HEROES NOMINATION FORM FOR MPN HEROES DocID: 1oHQS - View Document
	treatment of polycythemia vera with gleevec. gleevec and pha. gleevec on dr oz, gleevec researcher gleevec hydroxyurea factiva gleevec to treat metastatic melanoma cml gleevec molecular remission survival. free gleevec n DocID: 1mM1a - View Document
	Molecular Diagnosis of Myeloid Neoplasias and Solid Tumors First report of mutations detected in the gene for NF-E2 Technology Myeloproliferative Neoplasms (MPN) are a group of several distinct, but clinically related ma DocID: 1adts - View Document
	Novartis Pharmaceuticals Canada Inc. 385 Bouchard Blvd. Dorval, Quebec Canada H9S 1A9 www.novartis.ca DocID: 19fx5 - View Document